Turkish Pediatric Cancer Registry
Welcome,         Profile    Billing    Logout  
 7 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MARTELLI, Maria Paola
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Not yet recruiting
3
339
Europe, RoW
High intensity therapies, Low intensity therapies
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX
Acute Myeloid Leukemia, Relapse/Recurrence
01/28
01/28
GIMEMA, NCT04722848 / 2020-006048-15: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Recruiting
3
236
Europe
Ponatinib + Blinatumomab, Chemotherapy + Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Amgen S.r.l. via E. Tazzoli, 6 - 20154 - Milano, Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges, Switzerland
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
09/27
09/27
NCT04475731 / 2020-003912-28: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Active, not recruiting
2
67
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
11/24
11/24
NCT04342962 / 2020-001543-94: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Recruiting
2
50
Europe
tagraxofusp
Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia
04/23
04/25
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting
N/A
60
Europe
Dasatinib and blinatumomab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia
05/24
05/24
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
IMMONC0002, NCT05430971: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Recruiting
N/A
200
Europe, Canada, US, RoW
Immune Oncology Research Institute
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
07/32
07/32
Kutluk, Tezer
IMMONC0002, NCT05430971: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Recruiting
N/A
200
Europe, Canada, US, RoW
Immune Oncology Research Institute
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
07/32
07/32
Al-Jadiry, Mazin Faisal
IMMONC0002, NCT05430971: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Recruiting
N/A
200
Europe, Canada, US, RoW
Immune Oncology Research Institute
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
07/32
07/32
Ghali, Hasanein Habeeb
IMMONC0002, NCT05430971: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Recruiting
N/A
200
Europe, Canada, US, RoW
Immune Oncology Research Institute
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
07/32
07/32

Download Options